Stoke Therapeutics (STOK) Gains from Sales and Divestitures (2024)
Stoke Therapeutics (STOK) recorded quarterly Gains from Sales and Divestitures of $93000.0 in Q4 2024.
Stoke Therapeutics (STOK) Gains from Sales and Divestitures (2024) Analysis & Trends
Stoke Therapeutics' Gains from Sales and Divestitures history runs 1 years deep, the most recent figure standing at $93000.0 for Q4 2024.
- In Q4 2024, Gains from Sales and Divestitures changed N/A year-over-year to $93000.0; the TTM figure through Dec 2024 stood at $93000.0 (changed N/A YoY), while the FY2024 annual figure was $93000.0, changed N/A from the prior year.
- Gains from Sales and Divestitures was $93000.0 for Q4 2024 at Stoke Therapeutics.
- In the past five years, Gains from Sales and Divestitures ranged from a high of $93000.0 in Q4 2024 to a low of $93000.0 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Stoke Therapeutics | 1.95 Bn | 1.95 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 93,000.00 |
| Dec 31, 2024 | 93,000.00 |